SCHEMBL334803

SCHEMBL334803

CCN(CCN)C(C)c1ccc(N2CCOCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 3/20 0.44
ALDH1A1 P00352 6/20 0.43
MAPT P10636 5/20 0.43
KDM4E B2RXH2 3/20 0.43
ALOX15 P16050 2/20 0.43
MAPK1 P28482 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
GAA P10253 1/20 0.43
ALOX12 P18054 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CYP17A1 P05093 1/20 0.42
AOC3 Q16853 3/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 2/20 0.39
HTT P42858 2/20 0.39
KMT2A Q03164 2/20 0.39
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244305 0.78 ALDH1A1 (0.42) RORCALDH1A1MAPTKDM4EALOX15
SCHEMBL334958 0.73 ALOX5 (0.44) ALDH1A1KDM4ELMNAHIF1A
SCHEMBL335079 0.73 TAAR1 (0.42) ALDH1A1MAPTMAPK1SMN1; SMN2TDP1
SCHEMBL334729 0.73 ROCK1 (0.39) AOC3MEN1KMT2A
SCHEMBL335097 0.73 ADRB2 (0.42) ALDH1A1L3MBTL1AOC3LMNAMEN1
SCHEMBL336063 0.73 NPSR1 (0.44) ALDH1A1MAPTKDM4ESMN1; SMN2L3MBTL1
SCHEMBL335260 0.73 HRH1 (0.45) AOC3CYP1A2
SCHEMBL24171019 0.72 ALDH1A1 (0.50) RORCALDH1A1MAPTKDM4EALOX15
SCHEMBL19928242 0.71 MEN1 (0.55) RORCALDH1A1MAPTKDM4EALOX15
SCHEMBL18012415 0.71 ALDH1A1 (0.52) RORCALDH1A1MAPTKDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 RORC 80/4885ALDH1A1 1939/4885MAPT 4302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.